share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  07/19 06:36
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.
Alterity Therapeutics Limited, a development stage enterprise listed on both ASX (ATH) and NASDAQ (ATHE), has filed a Form 6-K with the Securities and Exchange Commission for the month of July 2024. The report, which serves as a notification of foreign private issuer, indicates that Alterity Therapeutics has complied with the necessary provisions of the Corporations Act 2001 (Cth) as they apply to the company. On July 18, 2024, Alterity issued 75,220,800 fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company has confirmed that as of the date of the notice, it has adhered to the requirements of Chapter 2M of the Corporations Act, as well as sections 674 and 674A. Furthermore, there is no 'excluded information' as defined in sections 708A(7) and 708A(8) of the Corporations Act that needs to be disclosed. This Form 6-K is also incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3.
Alterity Therapeutics是一家发展阶段企业，已在ASX（代码：ATH）和纳斯达克（代码：ATHE）上市。该公司已向证券交易委员会提交了2024年7月的6-k表格。此报告作为外国私人发行人的通知，表明Alterity Therapeutics已遵守适用于该公司的《2001年公司法》的必要规定。2024年7月18日，Alterity在未根据《公司法》6D.2条款披露的情况下发行了75,220,800股已缴足普通股。该公司已确认，截至通知日期，它已遵守《公司法》第200万章的要求，以及674和674A条款的要求。此外，没有需要披露的《公司法》708A（7）和708A（8）条款定义的“排除信息”。这份6-k表格也被引用到Alterity的S-8和F-3表格的注册申请中。
Alterity Therapeutics是一家发展阶段企业，已在ASX（代码：ATH）和纳斯达克（代码：ATHE）上市。该公司已向证券交易委员会提交了2024年7月的6-k表格。此报告作为外国私人发行人的通知，表明Alterity Therapeutics已遵守适用于该公司的《2001年公司法》的必要规定。2024年7月18日，Alterity在未根据《公司法》6D.2条款披露的情况下发行了75,220,800股已缴足普通股。该公司已确认，截至通知日期，它已遵守《公司法》第200万章的要求，以及674和674A条款的要求。此外，没有需要披露的《公司法》708A（7）和708A（8）条款定义的“排除信息”。这份6-k表格也被引用到Alterity的S-8和F-3表格的注册申请中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息